Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arch Therapeutics Licenses Groundbreaking Intellectual Property on Hemostasis

Abstract:
Compositions That Stop Bleeding Promptly Could Revolutionize Surgical and Trauma Markets

Arch Therapeutics Licenses Groundbreaking Intellectual Property on Hemostasis

Cambridge, MA | Posted on April 28th, 2008

Arch Therapeutics, a life science company developing and commercializing compositions that promptly stop or control bleeding, today announced it has finalized a license agreement with the Massachusetts Institute of Technology.

The license provides Arch Therapeutics exclusive and non-exclusive commercialization rights to a range of patents and applications for technology that includes a family of compositions to control bleeding and the movement of other bodily substances.

Arch Therapeutics' compositions are clear, water-like, non-sticky materials that can be easily squirted through a syringe onto a bleeding wound. Arch Therapeutics expects the compositions to improve results in both surgical and trauma settings. The compositions should improve general outcomes for patients, decrease morbidity and mortality, and provide productivity and economic benefits in hospital environments and other settings. In early animal tests, the material has been used successfully to stop bleeding in the liver, spleen, femoral artery, eye and brain.

"Despite advances in patient care, the arsenal of tools that doctors use to stop bleeding still has its limitations. With our compositions, we expect to more efficiently control bleeding in surgical and trauma settings," said Rutledge Ellis-Behnke, research scientist in the MIT Department of Brain and Cognitive Sciences and a founder of Arch Therapeutics. Ellis-Behnke is a principle investigator on the research, and a co-author of the October 2006 Nanomedicine study that marked the first time nanotechnology has been used to achieve complete hemostasis, the process of halting bleeding from a damaged blood vessel.

The company is founded by Dr. Terrence Norchi, President & CEO; Steve Kelly, Chairman; and Ellis-Behnke. Prior to Arch Therapeutics, Dr. Norchi spent a decade in healthcare investing with a focus on pharmaceuticals, biotechnology and medical technology including being the lead portfolio manager of the second largest healthcare mutual fund in the world. Norchi also worked at Sanford C. Bernstein, Citigroup Asset Management and Putnam Investments and holds an MBA from MIT Sloan School of Management and a MD from NEOU College of Medicine. Steve Kelly, a serial entrepreneur, has helped build multiple New England-based companies He was most recently the founding CEO of Myomo, Inc., a MIT spinout that applies robotics to treat paralysis.

"Far from being a resolved problem, bleeding remains a leading cause of excess morbidity and mortality in hospitals, medical facilities and trauma settings around the world," said Norchi. "The current response to bleeding often puts additional demand on scarce or expensive resources within a constrained healthcare system. With our compositions, we plan to greatly improve patient care while also bringing significant economic benefits to the healthcare sector."

Unlike existing materials that are difficult to prepare, toxic, or inhibit healing, based on animal testing to date, Arch Therapeutics' novel synthetic products appear to be safe, easy to prepare and easy to use. Potential applications for the compositions include:

To stop bleeding: When applied to a wound, the material stops the bleeding promptly. Physicians interviewed believe that it will be valuable when used on diffuse oozing, visceral organ bleeding, and difficult to reach or visualize bleeding during surgery and trauma care.

To prevent bleeding: As a hemostatic agent applied prior to surgery, the compositions can proactively prevent bleeding, allowing surgeons to operate through it to control bleeding at the moment of its inception, as well as help maintain a clear field of vision.

"Discovering ways to control something so fundamental as bleeding has potentially huge implications for the medical field. The research and early milestones met by the Arch Therapeutics team are impressive and hold great promise for healthcare worldwide," said Floyd D. Loop, M.D., former head of the Cleveland Clinic and advisor to Arch Therapeutics.

Ellis-Behnke was a grant recipient from MIT's Deshpande Center for Technological Innovation. The center funds novel early-stage research and connects MIT's innovators with the resources needed to increase their commercial viability.

####

For more information, please click here

Contacts:
KMC Partners Public Relations
Sarah Mees, 617-682-3759

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanodiamonds Are Forever: A UCSB professor’s research examines 13,000-year-old nanodiamonds from multiple locations across three continents August 27th, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Nanotech Security Corp. to Acquire Fortress Optical Features Ltd., a Leading Producer of Banknote Security Features August 27th, 2014

Malvern specialists to deliver inaugural short course on polymer characterization at Interplas 2014 August 27th, 2014

Nanomedicine

The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment: Targeted therapy for hepatocellular carcinoma using nanotechnology August 27th, 2014

Introducing the multi-tasking nanoparticle: Versatile particles offer a wide variety of diagnostic and therapeutic applications August 26th, 2014

Symphony of nanoplasmonic and optical resonators leads to magnificent laser-like light emission August 26th, 2014

Silver Replaced with Copper Nanoparticles to Produce Antibacterial Fabrics August 25th, 2014

Announcements

Nanodiamonds Are Forever: A UCSB professor’s research examines 13,000-year-old nanodiamonds from multiple locations across three continents August 27th, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Nanotech Security Corp. to Acquire Fortress Optical Features Ltd., a Leading Producer of Banknote Security Features August 27th, 2014

Malvern specialists to deliver inaugural short course on polymer characterization at Interplas 2014 August 27th, 2014

Patents/IP/Tech Transfer/Licensing

AQUANOVA receives Technology Leadership Award 2014 FROST & SULLIVAN honors NovaSOL® Technology again August 12th, 2014

Blacktrace Holdings Ltd. to in-license PerkinElmer Technology August 8th, 2014

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE